Quick Answer
Maze Therapeutics, Inc. reported Total Revenue of $167.50 million for fiscal year 2024.
Maze Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenue | — | $167.50M | — |
| Revenue (ASC 606) | — | $167.50M | — |
| Net Income | -$131.12M -351.0% |
$52.23M | — |
| Diluted EPS | -$3.05 -344.0% |
$1.25 | — |
| Total Assets | $397.13M +65.1% |
$240.54M | — |
| Cash and Equivalents | $189.25M -3.8% |
$196.81M | — |
| Stockholders Equity | $354.97M +214.1% |
-$311.18M +16.8% |
-$373.85M |
| R&D Expense | $108.45M +29.9% |
$83.50M | — |
| Operating Income | -$142.90M -348.1% |
$57.59M | — |
| Shares Outstanding | 49.34M +1916.3% |
2.45M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2025 | $0.00 | -100.0% | -100.0% |
| Revenue (ASC 606) | June 30, 2025 | $0.00 | -100.0% | -100.0% |
| Net Income | September 30, 2025 | -$30.09M | -21.6% | +10.7% |
| Diluted EPS | September 30, 2025 | -$0.66 | +93.6% | +14.3% |
| Total Assets | September 30, 2025 | $422.06M | — | +39.1% |
| Cash and Equivalents | September 30, 2025 | $316.77M | +111.7% | +19.7% |
| Stockholders Equity | September 30, 2025 | $379.44M | +233.4% | +44.7% |
| R&D Expense | September 30, 2025 | $25.19M | +26.9% | -10.4% |
| Operating Income | September 30, 2025 | -$32.97M | -36.1% | +9.6% |
| Shares Outstanding | September 30, 2025 | 48.08M | — | +9.6% |
- Maze Therapeutics, Inc. reported Total Revenue of $167.50 million for fiscal year 2024.
- Maze Therapeutics, Inc. reported Revenue (ASC 606) of $167.50 million for fiscal year 2024.
- Maze Therapeutics, Inc. reported Net Income of -$131.12 million for fiscal year 2025.
- Maze Therapeutics, Inc. showed a decrease of -351.0% in Net Income compared to the prior fiscal year.
- Maze Therapeutics, Inc. reported Diluted EPS of $3.05 per share (loss) for fiscal year 2025.
- Maze Therapeutics, Inc. showed a decrease of -344.0% in Diluted EPS compared to the prior fiscal year.
- Maze Therapeutics, Inc. reported Total Assets of $397.13 million for fiscal year 2025.
- Maze Therapeutics, Inc. showed an increase of +65.1% in Total Assets compared to the prior fiscal year.
- Maze Therapeutics, Inc. reported Cash and Equivalents of $189.25 million for fiscal year 2025.
- Maze Therapeutics, Inc. showed a decrease of -3.8% in Cash and Equivalents compared to the prior fiscal year.
- Maze Therapeutics, Inc. reported Stockholders Equity of $354.97 million for fiscal year 2025.
- Maze Therapeutics, Inc. showed an increase of +214.1% in Stockholders Equity compared to the prior fiscal year.
- Maze Therapeutics, Inc. reported R&D Expense of $108.45 million for fiscal year 2025.
- Maze Therapeutics, Inc. showed an increase of +29.9% in R&D Expense compared to the prior fiscal year.
- Maze Therapeutics, Inc. reported Operating Income of -$142.90 million for fiscal year 2025.
- Maze Therapeutics, Inc. showed a decrease of -348.1% in Operating Income compared to the prior fiscal year.
- Maze Therapeutics, Inc. reported Shares Outstanding of 49.34 million shares for fiscal year 2025.
- Maze Therapeutics, Inc. showed an increase of +1916.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: